Table 1 Baseline characteristics of previously treated patients and study eyes (intent-to-treat population)
Characteristic | DEX 0.7 | Sham |
|---|---|---|
n = 247 | n = 261 | |
Patients | ||
Mean age (SD), yr | 63.0 (8.3) | 63.0 (9.1) |
Male, n (%) | 150 (60.7) | 168 (64.4) |
Caucasian, n (%) | 188 (76.1) | 192 (73.6) |
Mean diabetes duration (SD), yr | 16.4 (8.7) | 16.2 (9.7) |
Type 2 diabetes, n (%) | 220 (89.1) | 238 (91.2) |
Mean HbA1c (SD), % | 7.5 (1.1) | 7.5 (1.0) |
≤8 %, n (%) | 168 (68.0) | 189 (72.4) |
Mean DME duration (SD), mo | 27.3 (26.3) | 31.9 (28.6) |
Study eyes | ||
Lens status, n (%) | ||
Phakic | 182 (73.7) | 179 (68.6) |
Pseudophakic | 65 (26.3) | 82 (31.4) |
Mean BCVA (SD), ETDRS letters | 55.2 (9.6) | 56.1 (9.1) |
Mean CRT (SD), μm | 478 (153) | 472 (131) |
Prior DME treatment, n (%) | 247 (100) | 261 (100) |
Laser | 231 (93.5) | 243 (93.1) |
Intravitreal triamcinolone acetonide | 58 (23.5) | 61 (23.4) |
Intravitreal anti-VEGF | 25 (10.1) | 26 (10.0) |
At least 2 of the 3 types of treatment | 61 (24.7) | 57 (21.8) |
No prior DME treatment, n (%) | 0 (0) | 0 (0) |